Nonprofit founder and CEO, Craig Martin, notes that the industry will likely see more alternative gene therapy commercialisation models in the future.

Shares rose 5% for Novo Nordisk on the approval of oral Wegovy as it looks to ease market pressures with a significant ...

Genentech, a subsidiary of the Roche Group, has received the US FDA accelerated approval for Lunsumio VELO SC formulation to ...

As we head into the new year, now is the time to look back on the activity seen in the pharma space in 2025 and consider what ...

Ipsen first looked to add an ADC to its portfolio via a deal that would have been worth up to $900m with Sutro Biopharma in ...

The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially growing the company’s future revenue ...

With the latest batch’s agreements, only three out of the 17 drugmakers initially targeted by Trump have not signed pricing ...

MEDIPOST has announced a multi-year exclusive partnership with Teikoku Seiyaku to commercialise CARTISTEM, an allogeneic stem ...

AstraZeneca's Andexxa will no longer be sold or manufactured in the US following FDA concerns around the drug's association ...

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option ...

Eli Lilly has now submitted a new drug application (NDA) for GLP-1RA orforglipron to the FDA for use in adults with obesity.

Novartis has reached an agreement with the US government with the aim of reducing the price of innovative medicines and ...